Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases.

Hypercalcaemia in chronic lymphatic leukaemia.

A 75 year old woman with a 13 year history of classical chronic lymphatic leukaemia (CLL) developed hypercalcaemia. Unlike previous reports, this was not associated with blastic transformation, hyperparathyroidism or features of multiple myeloma, but was due to classical CLL per se.

Unusual manifestation of multiple myeloma: focal affection of central nervous system in a patient with chronic lymphocytic leukaemia.

INTRODUCTION Involvement of the central nervous system as the first manifestation of multiple myeloma is very rare. AIM To present an unusual case of the primomanifestation of a multiple myeloma in the form of a focal affection of the central nervous system in a patient with chronic lymphocytic leukaemia. METHODS AND RESULTS A female patient diagnosed with chronic B-lymphocytic leukaemia wi...

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union

The Committee for Orphan Medicinal Products (COMP) evaluates prevalence of rare conditions as one of the criteria for granting an orphan designation with a prevalence threshold of 5 in 10.000. At the time of Marketing Authorisation (MA) these criteria are reassessed to ensure they are still met. The COMP has noted discordance between the prevalence of certain haematological malignancies at the ...

Our Experience in the Flowcytometric Diagnosis of Malignant Hemopathies

The discovery of monoclonal antibodies made possible the immunological investigation of malignant hemopathies, facilitating the positive diagnosis. We are presenting several cases of acute leukaemia, chronic lymphoblastic leukaemia and one of multiple myelomas in which flowcytometry was useful for establishing the diagnosis. Today, flowcytometry represents an indispensable instrument for the ma...

MHRA demonstrated that Gammaplex is effective as replacement therapy in primary immunodeficiency syndromes and treatment of myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and for the treatment of children with congenital AIDS